A close-up of a document

AI-generated content may be incorrect.

**TPRO01B: Compliance with with EQ-5D Form; Intent-to-treat Population (Study ARN-509-003)**

Placebo Apalutamide Total

Number of Forms,n(%) Number of Forms,n(%) Number of Forms,n(%)

Expected Received Missing Expected Received Missing Expected Received Missing

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baseline | 398 | 393 (98.7%) | 5 (1.3%) | 803 | 790 (98.4%) | 13 (1.6%) | 1201 | 1183 (98.5%) | 18 (1.5%) |
| Cycle 2 | 391 | 386 (98.7%) | 5 (1.3%) | 788 | 777 (98.6%) | 11 (1.4%) | 1179 | 1163 (98.6%) | 16 (1.4%) |
| Cycle 3 | 383 | 380 (99.2%) | 3 (0.8%) | 774 | 767 (99.1%) | 7 (0.9%) | 1157 | 1147 (99.1%) | 10 (0.9%) |
| Cycle 4 | 373 | 371 (99.5%) | 2 (0.5%) | 753 | 738 (98.0%) | 15 (2.0%) | 1126 | 1109 (98.5%) | 17 (1.5%) |
| Cycle 5 | 358 | 351 (98.0%) | 7 (2.0%) | 727 | 715 (98.3%) | 12 (1.7%) | 1085 | 1066 (98.2%) | 19 (1.8%) |
| Cycle 6 | 303 | 301 (99.3%) | 2 (0.7%) | 701 | 693 (98.9%) | 8 (1.1%) | 1004 | 994 (99.0%) | 10 (1.0%) |
| Cycle 7 | 287 | 283 (98.6%) | 4 (1.4%) | 683 | 673 (98.5%) | 10 (1.5%) | 970 | 956 (98.6%) | 14 (1.4%) |
| Cycle 9 | 268 | 263 (98.1%) | 5 (1.9%) | 660 | 645 (97.7%) | 15 (2.3%) | 928 | 908 (97.8%) | 20 (2.2%) |
| Cycle 11 | 223 | 221 (99.1%) | 2 (0.9%) | 629 | 612 (97.3%) | 17 (2.7%) | 852 | 833 (97.8%) | 19 (2.2%) |
| Cycle 13 | 201 | 199 (99.0%) | 2 (1.0%) | 603 | 589 (97.7%) | 14 (2.3%) | 804 | 788 (98.0%) | 16 (2.0%) |
| Cycle 17 | 140 | 135 (96.4%) | 5 (3.6%) | 471 | 457 (97.0%) | 14 (3.0%) | 611 | 592 (96.9%) | 19 (3.1%) |
| Cycle 21 | 87 | 83 (95.4%) | 4 (4.6%) | 367 | 351 (95.6%) | 16 (4.4%) | 454 | 434 (95.6%) | 20 (4.4%) |
| Cycle 25 | 54 | 53 (98.1%) | 1 (1.9%) | 264 | 257 (97.3%) | 7 (2.7%) | 318 | 310 (97.5%) | 8 (2.5%) |
| Cycle 29 | 35 | 35 (100.0%) | 0 | 171 | 167 (97.7%) | 4 (2.3%) | 206 | 202 (98.1%) | 4 (1.9%) |
| Cycle 33 | 13 | 12 (92.3%) | 1 (7.7%) | 94 | 88 (93.6%) | 6 (6.4%) | 107 | 100 (93.5%) | 7 (6.5%) |
| Cycle 37 | 4 | 4 (100.0%) | 0 | 35 | 34 (97.1%) | 1 (2.9%) | 39 | 38 (97.4%) | 1 (2.6%) |
| Cycle 41 | 1 | 1 (100.0%) | 0 | 14 | 13 (92.9%) | 1 (7.1%) | 15 | 14 (93.3%) | 1 (6.7%) |
| Cycle 45 | 0 |  |  | 4 | 4 (100.0%) | 0 | 4 | 4 (100.0%) | 0 |
| End Of Treatment | 282 | 214 (75.9%) | 68 (24.1%) | 317 | 232 (73.2%) | 85 (26.8%) | 599 | 446 (74.5%) | 153 (25.5%) |
| 4 Month Follow-Up | 215 | 150 (69.8%) | 65 (30.2%) | 205 | 147 (71.7%) | 58 (28.3%) | 420 | 297 (70.7%) | 123 (29.3%) |
| 8 Month Follow-Up | 165 | 121 (73.3%) | 44 (26.7%) | 149 | 105 (70.5%) | 44 (29.5%) | 314 | 226 (72.0%) | 88 (28.0%) |
| 12 Month Follow-Up | 114 | 78 (68.4%) | 36 (31.6%) | 109 | 69 (63.3%) | 40 (36.7%) | 223 | 147 (65.9%) | 76 (34.1%) |

Apalutamide = Apalutamide + ADT (androgen deprivation therapy, ie, lutenizing hormone releasing hormone or surgical castration); Placebo = ADT only. Expected number of forms: the form that a subject is expected to complete at the scheduled visit before discontinuing the treatment.

Received number of forms: the number of subjects with at least one assessment completed at the corresponding visit. Note that percentages calculated with the number of expected forms in each group as denominator.

[TPRO01B.RTF] [JNJ-56021927\ARN-509-003\DBR\_IA\RE\_IA\PROD\TPRO01B.SAS] 10AUG2017, 21:06